Baxter reports Q3 adjusted EPS 68c, consensus 68c

Reports Q3 revenue $3.71B, consensus $3.69B. “Baxter continues to successfully execute upon the slate of strategic actions we announced at the outset of 2023,” said Jose (Joe) E. Almeida, chairman, president and chief executive officer. “These initiatives are centered on enhancing business performance and increasing innovation, to drive incremental value for all of our stakeholders. This progress is demonstrated across several actions this quarter, including the completion of the BioPharma Solutions divestiture, verticalization of our four business segments and solid third-quarter performance. These milestones are critical in building momentum on Baxter’s ongoing transformation journey.”